TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Status:
RECRUITING
Trial end date:
2026-03-09
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM).
Phase:
PHASE2
Details
Lead Sponsor:
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd